3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
9
Neoplasms
8
Prostatic Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Premenopausal HR+/HER2- Metastatic Breast Cancer
1
Polycythemia Vera
1
Pathologic Complete Response
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Interventions
Temozolomide
109
Magnetic Resonance Spectroscopy
52
Bevacizumab
52
Radiotherapy
44
Irinotecan
27
Blood Specimen Collection
19
Surgical Procedures, Operative
16
Radiation
15
Aminolevulinic Acid
15
Carboplatin
13
fluorodopa F 18
12
Nivolumab
12
Radiotherapy, Intensity-Modulated
11
Carmustine
11
Radiosurgery
10
Magnetic Resonance Imaging
10
pembrolizumab
9
Topotecan
9
Specimen Handling
9
Everolimus
9
Erlotinib Hydrochloride
9
Biopsy
9
poly ICLC
8
Surveys and Questionnaires
8
Standard of Care
8
Etoposide
8
Drug Therapy
8
Lomustine
7
Filgrastim
7
Cyclophosphamide
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Glioma
×
talazoparib
×
Clear all
NCT04740190
2025-06-11
TAC-GReD
The University of Hong Kong
Phase 2
Completed
33 enrolled